The BMP2 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma 143B cell line, offering targeted disruption of the BMP2 gene for loss-of-function studies. This polyclonal format consists of a genetically heterogeneous pool of cells, enabling robust analysis of BMP2-dependent phenotypes while avoiding the artifacts that may arise from single-cell clonal selection. The model is suitable for a wide range of functional assays in bone biology and cancer research.
Derived from the TE85 osteosarcoma line, 143B cells are a widely utilized model for osteosarcoma and bone metastasis due to their aggressive in vivo behavior and partial osteoblastic characteristics. The TK-deficient background of 143B provides a selectable marker system, facilitating in vivo tracking and genetic manipulation studies. This host cell line retains the capacity for osteogenic differentiation, making it a relevant system in which to examine the consequences of BMP2 ablation on osteoblast-like phenotypes and tumor cell behavior.
BMP2 encodes a TGF-beta superfamily ligand that initiates bone and cartilage formation. By engaging heteromeric receptors BMPR1A, BMPR1B, and BMPR2, it triggers phosphorylation of SMAD1/5/8, which complex with SMAD4 and translocate to the nucleus to activate transcription of osteogenic targets including ID1, DLX5, ALPL, BGLAP, and COL1A1. Extracellular regulation is provided by antagonists Noggin (NOG), Chordin (CHRD), and Gremlin (GREM1), while Endoglin (ENG) fine-tunes signaling. Upstream regulators such as RUNX2, TGFB1, WNT3A, and vitamin D modulate BMP2 expression, integrating multiple pathways.
Within the 143B osteosarcoma background, loss of BMP2 alters osteoblast-like differentiation programs and tumor microenvironmental interactions. This polyclonal knockout population enables detailed examination of BMP2-dependent contributions to osteosarcoma cell migration, invasion, and bone lesion formation, as well as investigation of signaling crosstalk with TGF-beta, MAPK, and Wnt pathways that are frequently dysregulated in bone malignancies.
The BMP2 Knockout 143B Polyclonal Cells support diverse research applications including osteosarcoma biology, bone metastasis, and osteoblast differentiation. Typical experiments involve assessing SMAD1/5/8 phosphorylation by Western blotting, measuring osteogenic gene expression (ALPL, BGLAP, COL1A1) via RT-qPCR, and evaluating matrix mineralization with Alizarin Red S staining. Additional applications encompass cell migration assays, RNA-seq transcriptomics, and immunofluorescence for SMAD translocation. For purchasing or support, contact Ascent Research.
